National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 6 of 2004)

Overview

The National Health Act 1953 was enacted to address the need for a comprehensive framework governing health services in Australia, including the administration of pharmaceutical benefits. The Act was established by the Parliament of Australia with a policy objective to provide all Australians with access to essential health services and to ensure the availability and affordability of necessary medications through the Pharmaceutical Benefits Scheme (PBS). A specific legislative instrument, F2007B00633, was introduced as a declaration under subsection 85(2AA) of the Act, to discontinue the listing of certain drugs and medicinal preparations on the PBS. This declaration, effective from 1 May 2004, removes Cefotetan Disodium, Nefazodone Hydrochloride, and Oestrogens—Conjugated and Medroxyprogesterone Acetate from the scope of Part VII of the National Health Act 1953, thus ceasing their coverage under the PBS. This decision was made following advice from the Pharmaceutical Benefits Advisory Committee, reflecting a strategic adjustment to the scheme's coverage based on clinical and economic considerations.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to the cessation of the pharmaceutical benefits scheme coverage for specific drugs and medicinal preparations listed in the Schedule. The Act affects pharmaceutical entities and practitioners by removing the entitlement to subsidised medication for the specified drugs. Geographically, the Act operates nationally, as it is a Commonwealth legislation. This declaration does not apply to entities or individuals outside the scope of the National Health Act 1953 or to drugs not listed in the Schedule. The scope of the Act is further extended or restricted by subordinate instruments, which may include amendments or additions to the Schedule to reflect changes in medical practices or pharmaceutical availability. The exclusions are limited to the specific drugs listed, and any other drugs not mentioned remain subject to the provisions of the National Health Act 1953.

Key Provisions

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953, made by Joan Corbett on behalf of the Minister for Health and Ageing, identifies certain drugs and medicinal preparations that are to be removed from the list of those covered by Part VII of the Act. Section 1 of the Declaration specifies that it takes effect from 1 May 2004, while Section 2 lists the drugs that will cease to be covered by the Pharmaceutical Benefits Scheme (PBS), which are Cefotetan Disodium, Nefazodone Hydrochloride, and Oestrogens—Conjugated and Medroxyprogesterone Acetate. These drugs are detailed in the Schedule to the Declaration. The obligations imposed by this Declaration are primarily on the Pharmaceutical Benefits Advisory Committee and the Minister for Health and Ageing. The Advisory Committee is responsible for providing advice to the Minister on the inclusion or exclusion of drugs from the PBS, as mandated by subsection 85(2AB). The Minister, in turn, must make a declaration in accordance with subsection 85(2AA) based on this advice. The Act ensures that the process for modifying the list of covered drugs is both consultative and evidence-based, requiring the Minister to follow the advice of the Advisory Committee. Breaches of the provisions in the National Health Act 1953 may result in various penalties depending on the nature of the offence. For example, under section 110 of the Act, any person who contravenes the provisions regarding the listing of drugs on the PBS could be subject to fines. The maximum penalties for such offences are stipulated in section 111, which provides for fines up to a certain amount for individuals and higher penalties for corporations, reflecting the severity of the breach. Additionally, there may be civil consequences for suppliers or manufacturers who continue to claim benefits for drugs that have been removed from the PBS, potentially resulting in financial restitution or other corrective measures.